Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Two Formulations of LY03003 in Parkinson's Disease
NCT03589066Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- May 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Rotigotine extended-release microspheres in Parkinson's disease (PD) (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Maximum Plasma Concentration at 22 days, Area Under the Curve to Last Measurable Concentration at 22 days and 1 more. Started May 2018; status: completed.
02
Drugs
Rotigotine extended-release microspheres
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03589066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589066.